• Gene fusion; HGNC; HGNC:13575; BRD4 + HGNC; HGNC:29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT (PubMed=15994877; PubMed=29348827).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg267Gln (c.800G>A); ClinVar=VCV000127823; Zygosity=Homozygous (DepMap=ACH-000143).
  

PubMed=10944559; DOI=10.1093/jnci/92.16.1355
Dang T.P., Gazdar A.F., Virmani A.K., Sepetavec T., Hande K.R., Minna J.D., Roberts J.R., Carbone D.P.
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer.
J. Natl. Cancer Inst. 92:1355-1357(2000)

PubMed=15994877; DOI=10.1136/jmg.2004.029686; PMCID=PMC1736105
Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Gonzalez A., Gazdar A.F., Minna J.D., Carbone D.P., Dang T.P.
Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro.
J. Med. Genet. 42:558-564(2005)

PubMed=20679594; DOI=10.1093/jnci/djq279; PMCID=PMC2935474
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=24736545; DOI=10.1158/0008-5472.CAN-13-2658; PMCID=PMC4097982
Wang R.-R., Liu W., Helfer C.M., Bradner J.E., Hornick J.L., Janicki S.M., French C.A., You J.-X.
Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Cancer Res. 74:3332-3343(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29348827; DOI=10.18632/oncotarget.22862; PMCID=PMC5762512
Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.
Oncotarget 8:112313-112329(2017)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028; PMCID=PMC5935540
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31803961; DOI=10.1002/jcb.29564; PMCID=PMC7496084
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)